A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
← catalyst calendarNCT07688213 · readout in 1,076 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
160estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-28 | actual | When the study began enrolling |
| Primary completion | 2029-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Dementia, Alzheimer's Type
- Alzheimer's Disease
Interventions
- Drug: SAR448851
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217
measured From baseline to Week 48
Part B: Number of participants with treatment-emergent adverse events (TEAE), including ARIA-E and ARIA-H by brain MRI, laboratory assessments, vital sign measurements, ECGs and the C-SSRS
measured From Week 48 to Week 96
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed